Literature DB >> 17132779

Hypertrophy and atrophy of the heart: the other side of remodeling.

Peter Razeghi1, Heinrich Taegtmeyer.   

Abstract

The size of a cardiomyocyte is determined by relative rates of protein synthesis and degradation. Signaling pathways regulating myocardial protein synthesis have been extensively investigated, not the least because in patients hypertrophy increases cardiovascular morbidity and mortality. Until now strategies to reverse hypertrophy have relied on the inhibition of prohypertrophic signaling pathways. Here we review signaling pathways of atrophy in the heart and we present evidence in support of the idea that activating proatrophic signaling pathways in the presence of prohypertrophic signaling may be an attractive strategy to reverse hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17132779     DOI: 10.1196/annals.1380.011

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  16 in total

1.  Bridge to recovery: understanding the disconnect between clinical and biological outcomes.

Authors:  Stavros G Drakos; Abdallah G Kfoury; Josef Stehlik; Craig H Selzman; Bruce B Reid; John V Terrovitis; John N Nanas; Dean Y Li
Journal:  Circulation       Date:  2012-07-10       Impact factor: 29.690

Review 2.  The aging heart and post-infarction left ventricular remodeling.

Authors:  Henry Shih; Brian Lee; Randall J Lee; Andrew J Boyle
Journal:  J Am Coll Cardiol       Date:  2011-01-04       Impact factor: 24.094

Review 3.  Taking pressure off the heart: the ins and outs of atrophic remodelling.

Authors:  Kedryn K Baskin; Heinrich Taegtmeyer
Journal:  Cardiovasc Res       Date:  2011-02-25       Impact factor: 10.787

4.  Interferon-γ causes cardiac myocyte atrophy via selective degradation of myosin heavy chain in a model of chronic myocarditis.

Authors:  Pippa F Cosper; Pamela A Harvey; Leslie A Leinwand
Journal:  Am J Pathol       Date:  2012-10-08       Impact factor: 4.307

5.  Mechanisms and management of doxorubicin cardiotoxicity.

Authors:  Y Shi; M Moon; S Dawood; B McManus; P P Liu
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

Review 6.  The cardiomyocyte circadian clock: emerging roles in health and disease.

Authors:  David J Durgan; Martin E Young
Journal:  Circ Res       Date:  2010-03-05       Impact factor: 17.367

7.  Weaving hypothesis of cardiomyocyte sarcomeres: discovery of periodic broadening and narrowing of intercalated disk during volume-load change.

Authors:  Makoto Yoshida; Eiketsu Sho; Hiroshi Nanjo; Masato Takahashi; Mikio Kobayashi; Kouiti Kawamura; Makiko Honma; Masayo Komatsu; Akihiro Sugita; Misa Yamauchi; Takahiro Hosoi; Yukinobu Ito; Hirotake Masuda
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

8.  Phylogenetic origin of LI-cadherin revealed by protein and gene structure analysis.

Authors:  R Jung; M W Wendeler; M Danevad; H Himmelbauer; R Gessner
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

Review 9.  Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.

Authors:  Mark J Ranek; Xuejun Wang
Journal:  Curr Hypertens Rep       Date:  2009-12       Impact factor: 5.369

10.  Prenatal Alcohol Exposure Causes Adverse Cardiac Extracellular Matrix Changes and Dysfunction in Neonatal Mice.

Authors:  Van K Ninh; Elia C El Hajj; Alan J Mouton; Jason D Gardner
Journal:  Cardiovasc Toxicol       Date:  2019-10       Impact factor: 3.231

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.